Bioventix PLC
LSE:BVXP

Watchlist Manager
Bioventix PLC Logo
Bioventix PLC
LSE:BVXP
Watchlist
Price: 3 170 GBX -4.66% Market Closed
Market Cap: 165.5m GBX
Have any thoughts about
Bioventix PLC?
Write Note

Net Margin
Bioventix PLC

63.7%
Current
64%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
63.7%
=
Net Income
8.7m
/
Revenue
13.6m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
UK
Bioventix PLC
LSE:BVXP
165.5m GBP
64%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
311.8B USD
9%
US
Amgen Inc
NASDAQ:AMGN
140.7B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.7B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
134.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-14%
Country UK
Market Cap 165.5m GBP
Net Margin
64%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 311.8B USD
Net Margin
9%
Country US
Market Cap 140.7B USD
Net Margin
13%
Country US
Market Cap 115.7B USD
Net Margin
0%
Country US
Market Cap 102.7B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 134.4B AUD
Net Margin
18%
Country US
Market Cap 78B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

Bioventix PLC
Glance View

Market Cap
165.5m GBX
Industry
Biotechnology

Bioventix Plc engages in the development and supply of antibodies. The company is headquartered in Farnham, Surrey and currently employs 17 full-time employees. The company went IPO on 2014-04-29. The principal activity of the Company is the development and supply of antibodies. The firm specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics, such as in automated immunoassays used in blood testing. The firm offers a portfolio of antibodies to customers for both commercial use and research and development (R&D) purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The firm also supplies antibody products and services to multinational clinical diagnostics companies. The firm sells its products through direct sales and through distributors.

BVXP Intrinsic Value
3 026.52 GBX
Overvaluation 5%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
63.7%
=
Net Income
8.7m
/
Revenue
13.6m
What is the Net Margin of Bioventix PLC?

Based on Bioventix PLC's most recent financial statements, the company has Net Margin of 63.7%.